Eritrotex Mechanism of Action





Averroes Pharma
Full Prescribing Info
Pharmacology: Pharmacodynamics: Erythromycin binds to the ribosomes of bacteria and affects protein synthesis without affecting nucleic acid synthesis. Erythromycin does not bind to cytoplasmic membranes of the host cells. This is a possible explanation of its low toxicity and safety record.
Erythromycin is bacteriostatic and bactericidal depending on its concentration and the type of organism. It inhibits protein synthesis by binding to ribosmal subunits, inhibiting translocation of aminocyl transfer RNA and inhibiting polypeptide synthesis without causing any alteration in the nucleic acid cycle.
Pharmacokinetics: Distribution: The apparent volume of distribution of Erythromycin is around 45% of body weight in normal subjects. This large distribution volume is consistent with the extensive tissue penetration of erythromycin.
Erythromycin diffuses readily into most body fluids, except the cerebrospinal fluid. However, in cases of meningeal inflammation, higher concentrations are apparent.
Metabolism: In studies using rabbit microsomes it has been shown that erythromycin is demethylated to des-N-methyl Erythromycin and formaldehyde.
Excretion: In the presence of normal hepatic function, Erythromycin is concentrated in the liver and excreted in the bile; the effect of hepatic dysfunction on excretion of Erythromycin by the liver is not known.
From 12% to 15% of intravenously administered Erythromycin is excreted in active form in the urine.
The drug is also excreted in the faeces.
Half-Life: The plasma elimination half-life in patients with normal renal function is about 2 hours. In severe renal impairment the half-life may be prolonged to between 4 and 7 hours.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in